Skip to content
Module 2, Potential emergencies

Anaphylactic shock

A 38-year-old asthmatic woman, monitored in the PACU after an arthroscopy (monitor and nasal capnography), receives an IV antibiotic. Within minutes: itching, hives, breathing difficulty and feeling faint.

  • Adult
  • Indicative length: 10 min
  • 2 sources
Play this case with the free 30-min trial

Free trial: 30 minutes, once per e-mail address and per card. Your card is checked, with no charge.

Learning objectives

  • Recognise anaphylaxis: sudden involvement of the airway, breathing or circulation after exposure, with or without skin and mucosal signs (ERC 2025).
  • Stop the suspected administration immediately and call for help (doctor, internal number or 15).
  • Have adrenaline given without delay, as soon as anaphylaxis is suspected, by the authorised professional: IM route, 0.5 mg in adults (ERC 2025); IV titration if the patient is monitored and has venous access (ERC 2025; SFAR 2025).
  • Position according to the signs (lying with legs raised if shock, sitting with legs extended if breathing difficulty), high-flow oxygen.
  • Monitor progress (HR, BP, SpO2, capnography), have adrenaline repeated if there is no improvement, hand over.

Information points and sources

  1. According to ERC 2025, IM adrenaline 0.5 mg (lateral thigh) is injected as soon as anaphylaxis is suspected, then repeated if there is no improvement within 5 minutes (key points) or after 3 to 5 minutes depending on the clinical response (text).

    Source: ERC Guidelines 2025, Special Circumstances in Resuscitation, Anaphylaxis (points clés et Give adrenaline)

    Open the source
  2. According to SFAR 2025, perioperatively, adrenaline is injected without delay (grades II to IV) and titrated IV under monitoring: adult 10 to 20 µg (grade II) or 100 to 200 µg (grade III) every 2 min; IM (10 µg/kg, maximum 500 µg) is reserved for when there is no monitoring or venous access.

    Source: SFAR-SFA, RFE Diagnostic et prise en charge des réactions d'hypersensibilité immédiate périopératoires, 2025, R4.3.1, R4.3.3 à R4.3.5 et R4.3.8 (avis d'experts, accord fort)

    Open the source
  3. According to ERC 2025, if symptoms persist or if the patient is in a monitored area (intensive care, theatre, emergency department), IV adrenaline can be started at 0.1 µg/kg/min, titrated to response, by trained staff in a fully monitored patient.

    Source: ERC Guidelines 2025, Special Circumstances in Resuscitation, Anaphylaxis, Give adrenaline

    Open the source
  4. According to ERC 2025, every patient with anaphylaxis receives 100% oxygen at 15 L/min, then the flow is adjusted for a target SpO2 of 94 to 98%.

    Source: ERC Guidelines 2025, Special Circumstances in Resuscitation, Anaphylaxis, Give oxygen

    Open the source
  5. According to SFAR 2025 (R4.4.2), high-volume fluid loading is at least 10 mL/kg (grade II) or 20 mL/kg (grades III and IV) within 30 minutes; ERC 2025 proposes crystalloid boluses of 10 to 20 mL/kg, repeated according to response.

    Source: SFAR-SFA, RFE 2025, R4.4.2 (avis d'experts, accord fort) ; ERC Guidelines 2025, Special Circumstances, Anaphylaxis, Secure vascular access

    Open the source
  6. According to ERC 2025, the patient is neither sat up nor made to stand (the upright posture has been associated with deaths): lying with legs raised for venous return, or sitting with legs extended if the signs are respiratory without circulatory compromise.

    Source: ERC Guidelines 2025, Special Circumstances in Resuscitation, Anaphylaxis, approche initiale

    Open the source
  7. According to ERC 2025, antihistamines act slowly and must not delay adrenaline; ERC recommends not using corticosteroids routinely (expert opinion).

    Source: ERC Guidelines 2025, Special Circumstances in Resuscitation, Anaphylaxis, Role of steroids and antihistamines

    Open the source
  8. According to SFAR 2025 (R4.7), after a severe reaction (grade III or IV), monitoring continues in critical care or the PACU for at least 24 h after complete resolution of symptoms (expert opinion).

    Source: SFAR-SFA, RFE Hypersensibilité immédiate périopératoire, 2025, R4.7.1 et R4.7.2

    Open the source

This scenario runs inside the simulator. Its settings and steps stay in the product. The simulator is a teaching tool and is not a medical device.